{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T01:45:42Z","timestamp":1775699142471,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jcjo.2025.10.002","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T01:36:24Z","timestamp":1763602584000},"page":"437-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of 16-week extension of anti-VEGF therapy in neovascular age-related macular degeneration"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4122-5321","authenticated-orcid":false,"given":"Amy","family":"Basilious","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6129-5899","authenticated-orcid":false,"given":"Amelia T.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-1857","authenticated-orcid":false,"given":"Tom G.","family":"Sheidow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2025.10.002_bib0001","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/PPA.S347713","article-title":"Drivers of and barriers to adherence to neovascular age-related macular degeneration and diabetic macular edema treatment management plans: a multi-national qualitative study","volume":"16","author":"Giocanti-Aur\u00e9gan","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0002","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ophtha.2023.12.033","article-title":"Risk of endophthalmitis based on cumulative number of anti-VEGF intravitreal injections","volume":"131","author":"Israilevich","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0003","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1186\/s12913-019-4666-0","article-title":"Incremental economic burden associated with exudative age-related macular degeneration: a population-based study","volume":"19","author":"Kim","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0004","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/APO.0000000000000445","article-title":"Treat-and-extend regimens for the management of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy: consensus and recommendations from the Asia-Pacific Vitreo-retina Society","volume":"10","author":"Chaikitmongkol","year":"2021","journal-title":"Asia-Pacific J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0005","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41433-019-0747-x","article-title":"Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration","volume":"34","author":"Ross","year":"2020","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0006","doi-asserted-by":"crossref","first-page":"8952","DOI":"10.1038\/s41598-025-92832-w","article-title":"Recurrence of neovascular age-related macular degeneration after discontinuation of modified treat and extend treatment","volume":"15","author":"Lee","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0007","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1136\/bjophthalmol-2020-316514","article-title":"Aflibercept for age-related macular degeneration: 4-year outcomes of a \u2018treat-and-extend\u2019 regimen with exit-strategy","volume":"106","author":"Jaggi","year":"2022","journal-title":"Brit J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-19062-2","article-title":"Recurrence of neovascular age-related macular degeneration after cessation of treat and extend regimen","volume":"12","author":"Hirata","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.oret.2021.03.010","article-title":"Recurrent neovascular age-related macular degeneration after discontinuation of vascular endothelial growth factor inhibitors managed in a treat-and-extend regimen","volume":"6","author":"Aslanis","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0010","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/bjophthalmol-2020-317434","article-title":"Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence","volume":"105","author":"Daien","year":"2021","journal-title":"Brit J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0011","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.oret.2016.12.004","article-title":"Randomized trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: 2-year results of the TREX-AMD Study","volume":"1","author":"Wykoff","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0012","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND Study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0013","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1001\/jamaophthalmol.2019.5540","article-title":"Efficacy of a treat-and-extend regimen with ranibizumab in patients with neovascular age-related macular disease: a randomized clinical trial","volume":"138","author":"Kertes","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0014","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41433-022-02020-7","article-title":"Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis","volume":"37","author":"Rosenberg","year":"2023","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0015","first-page":"296","article-title":"Recommended guidelines for use of intravitreal aflibercept with a treat-and-extend regimen for the management of neovascular age-related macular degeneration in the Asia-Pacific region: report from a consensus panel","volume":"6","author":"Koh","year":"2017","journal-title":"Asia-Pacific J Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0016","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1007\/s00417-020-05048-1","article-title":"Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) \u2014 a meta-analysis","volume":"259","author":"Garweg","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0017","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00417-021-05526-0","article-title":"Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting","volume":"260","author":"Matsubara","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0018","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.3390\/jcm13154317","article-title":"Recurrence rate during 5-year period after suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration","volume":"13","author":"Chujo","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0019","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.oret.2019.05.013","article-title":"Outcomes of suspending VEGF inhibitors for neovascular age-related macular degeneration when lesions have been inactive for 3 months","volume":"3","author":"Nguyen","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0020","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jcjo.2025.10.002_bib0021","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1097\/IAE.0000000000003128","article-title":"Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration","volume":"41","author":"Mitchell","year":"2021","journal-title":"Retina"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418225004430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418225004430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:49:16Z","timestamp":1775695756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418225004430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0008418225004430"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2025.10.002","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of 16-week extension of anti-VEGF therapy in neovascular age-related macular degeneration","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2025.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}